Apimeds Pharmaceuticals US (APUS) Balance Sheet Analysis 2021-2025

Metric	2023	2024	LTM
Total Cash And Short-Term Investments	$0.41M	$0.003M	$6.987M
Net Receivables	-	-	-
Inventory	-	-	-
Prepaid Expenses And Other Current Assets	-	$9.602K	-
Other Current Assets	$0.012M	-	$2.099M
Total Current Assets	$0.422M	$0.013M	$9.086M
Property, Plant And Equipment	-	-	$34.188K
Goodwill And Intangible Assets	-	-	-
Long-Term Investments	-	-	-
Deferred Tax Assets	-	-	-
Other Noncurrent Assets	-	-	$129.74K
Total Noncurrent Assets	-	-	$163.928K
Other Assets	-	-	-
Total Assets	$0.422M	$0.013M	$9.25M

Metric	2023	2024	LTM
Total Payables	-	$487.141K	-
Accrued Expenses	$123.314K	$106.643K	-
Short-Term Debt	-	$250K	$500.1K
Current Portion Of Lease Obligations	-	-	-
Income Taxes Payable	-	-	-
Current Deferred Revenue	-	-	-
Other Current Liabilities	-	$180.55K	$589.284K
Total Current Liabilities	$0.123M	$1.024M	$1.089M
Long-Term Debt	$266.891K	$346.844K	-
Capital Lease Obligations	-	-	-
Noncurrent Deferred Revenue	-	-	-
Noncurrent Deferred Tax Liabilities	-	-	-
Other Noncurrent Liabilities	-	-	-
Total Noncurrent Liabilities	$266.891K	$346.844K	-
Other Liabilities	-	-	-
Total Liabilities	$0.39M	$1.371M	$1.089M

Metric	2023	2024	LTM
Treasury Stock	-	-	-
Preferred Stock	-	-	-
Common Stock	$205.5K	$79.039K	$125.76K
Retained Earnings	$-3.002M	$-4.392M	$-9.238M
Additional Paid-In Capital	$2.828M	$2.955M	-
Accumulated Other Comprehensive Income	-	-	-
Other Stockholders' Equity	-	-	$17.273M
Total Common Stockholders' Equity	$0.032M	$-1.358M	$8.161M
Minority Interest	-	-	-
Total Equity	$0.032M	$-1.358M	$8.161M
Total Liabilities And Equity	$0.422M	$0.013M	$9.25M

Metric	2023	2024	LTM
Total Investments	-	-	-
Total Debt	$266.891K	$596.844K	$500.1K
Net Debt	$-0.144M	$0.593M	$-6.487M

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Apimeds Pharmaceuticals US Balance Sheet

Balance Sheet Composition